MRI and thallium-201 SPECT in the prediction of survival in glioma

Neuroradiology

Volumn 54, Issue 6, 2012, Pages 539-546

  Vos, Maaike J ^a,b   Berkhof, Johannes ^a   Hoekstra, Otto S ^a   Bosma, Ingeborg ^a   Sizoo, Eefje M ^a   Heimans, Jan J ^a   Reijneveld, Jaap C ^a   Sanchez, Esther ^a   Lagerwaard, Frank J ^a   Buter, Jan ^a   Noske, David P ^a   Postma, Tjeerd J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL CENTER HAAGLANDEN   (Netherlands)

Author keywords

Glioma; MRI; Overall survival; Temozolomide; Thallium 201 SPECT

Indexed keywords

TEMOZOLOMIDE; THALLIUM 201;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER PROGNOSIS; CANCER SIZE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CRANIOTOMY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECURRENT CANCER; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL PREDICTION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; FEMALE; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NETHERLANDS; PREVALENCE; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; SURVIVAL RATE; THALLIUM RADIOISOTOPES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862863201     PISSN: 00283940     EISSN: 14321920     Source Type: Journal    
DOI: 10.1007/s00234-011-0908-5     Document Type: Article

References (46)

1. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280 (Pubitemid 20195640)
2. Vos MJ, Uitdehaag BMJ, Barkhof F et al (2003) Interobserver variability in the radiological assessment of response to chemotherapy in glioma. Neurology 60:826-830 (Pubitemid 36297368)
3. Cairncross JG, Macdonald DR, Pexman JH, Ives FJ (1988) Steroid-induced CT changes in patients with recurrent malignant glioma. Neurology 38:724-726
4. Watling CJ, Lee DH, Macdonald DR, Cairncross JG (1994) Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol 12:1886-1889 (Pubitemid 24349391)
5. Cairncross JG, Pexman JH, Rathbone MP, DelMaestro RF (1985) Postoperative contrast enhancement in patients with brain tumor. Ann Neurol 17:570-572 (Pubitemid 15055574)
6. Henegar MM, Moran CJ, Silbergeld DL (1996) Early postoperative magnetic resonance imaging following nonneoplastic cortical resection. J Neurosurg 84:174-179 (Pubitemid 26039466)
7. Ulmer S, Braga TA, Barker FG et al (2006) Clinical and radiographic features of peritumoral infarction following resection of glioblastoma. Neurology 67:1668-1670 (Pubitemid 44747942)
8. Finn MA, Blumenthal DT, Salzman KL, Jensen RL (2007) Transient postictal MRI changes in patients with brain tumors may mimic disease progression. Surg Neurol 67:246-250 (Pubitemid 46274888)
9. Kumar AJ, Leeds NE, Fuller GN et al (2000) Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 217:377-384
10. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453-461 (Pubitemid 351597795)
11. Taal W, Brandsma D, de Bruin HG et al (2008) Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113:405-410
12. Brandes AA, Franceschi E, Tosoni A et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192-2197
13. Desjardins A, Reardon DA, Herndon JE et al (2008) Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 14:7068-7073
14. Sathornsumetee S, Cao Y, Marcello JE et al (2008) Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 26:271-278
15. van den Bent MJ, Vogelmaum MA, Wen PY, Macdonald DR, Chang SM (2009) End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's criteria. J Clin Oncol 27:2905-2908
16. Vredenburgh JJ, Desjardins A, Herndon JE et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729 (Pubitemid 350086473)
17. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963-1972
18. Schwartz RB, Carvalho PA, Alexander E III et al (1991) Radiation necrosis vs high-grade recurrent glioma: differentiation by using dual-isotope SPECT with 201TI and 99mTc-HMPAO. AJNR Am J Neuroradiol 12:1187-1192
19. Kosuda S, Fujii H, Aoki S et al (1993) Reassessment of quantitative thallium-201 brain SPECT for miscellaneous brain tumors. Ann Nucl Med 7:257-263 (Pubitemid 24012437)
20. Lorberboym M, Mandell LR, Mosesson RE et al (1997) The role of thallium-201 uptake and retention in intracranial tumors after radiotherapy. J Nucl Med 38:223-226 (Pubitemid 27061599)
21. Vos MJ, Tony BN, Hoekstra OS et al (2007) Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in the detection of recurrent glioma. Nucl Med Commun 28:431-439 (Pubitemid 46684192)
22. Roesdi MF, Postma TJ, Hoekstra OS et al (1998) Thallium-201 SPECT as response parameter for PCV chemotherapy in recurrent glioma. J Neurooncol 40:251-255 (Pubitemid 29054662)
23. Kallen K, Geijer B, Malmstrom P et al (2000) Quantitative 201Tl SPET imaging in the follow-up of treatment for brain tumour: a sensitive tool for the early identification of response to chemotherapy? Nucl Med Commun 21:259-267
24. Vallejos V, Balana C, Fraile M et al (2002) Use of 201Tl SPECT imaging to assess the response to therapy in patients with high grade gliomas. J Neurooncol 59:81-90 (Pubitemid 34918716)
25. Vos MJ, Hoekstra OS, Barkhof F et al (2003) Thallium-201 singlephoton emission computed tomography as an early predictor of outcome in recurrent glioma. J Clin Oncol 21:3559-3565 (Pubitemid 46594046)
26. Vos MJ, Berkhof J, Postma TJ et al (2006) Thallium-201 SPECT: the optimal prediction of response in glioma therapy. Eur J Nucl Med Mol Imaging 33:222-227 (Pubitemid 43152890)
27. Tony B, Vos MJ, Berkhof J et al (2005) Interobserver variability in the semi-quantitative assessment of 201Tl SPECT in cerebral gliomas. Nucl Med Commun 26:45-48 (Pubitemid 40189624)
28. Klein JP, Moeschberger ML (1997) Survival analysis: techniques for censored and truncated data. New York, Springer, pp 271-282
29. Hamstra DA, Galban CJ, Meyer CR et al (2008) Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 26:3387-3394
30. Lev MH, Ozsunar Y, Henson JW et al (2004) Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas. AJNR Am J Neuroradiol 25:214-221 (Pubitemid 38235298)
31. Simon JM, Cornu P, Boisserie G et al (2002) Brachytherapy of glioblastoma recurring in previously irradiated territory: predictive value of tumor volume. Int J Radiat Oncol Biol Phys 53:67-74 (Pubitemid 34467054)
32. Grant R, Walker M, Hadley D et al (2002) Imaging response to chemotherapy with RMP-7 and carboplatin in malignant glioma: size matters but speed does not. J Neurooncol 57:241-245 (Pubitemid 34692632)
33. Sanai N, Berger MS (2008) Glioma extent of resection and its impact on patient outcome. Neurosurgery 62:753-766
34. Bleichner-Perez S, Le Jeune F, Dubois F et al (2007) 99mTc-MIBI brain SPECT as an indicator of the chemotherapy response of recurrent, primary brain tumors. Nucl Med Commun 28:888-894 (Pubitemid 350306779)
35. Herholtz K, Kracht LW, Heiss WD (2003) Monitoring the effect of chemotherapy in a mixed glioma by C-11-methionine PET. J Neuroimaging 13:269-271
36. Hu LS, Baxter LC, Smith KA et al (2009) Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between imageguided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 30:552-558
37. Oh J, Henry RG, Pirzkall A et al (2004) Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging 19:546-554 (Pubitemid 38619916)
38. Leimgruber A, Ostermann S, Yeon EJ et al (2006) Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial. Int J Radiat Oncol Biol Phys 64:869-875 (Pubitemid 43183587)
39. Law M, Oh S, Babb JS et al (2006) Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging - prediction of patient clinical response. Radiology 238:658-667 (Pubitemid 43134379)
40. Cao Y, Tsien CI, Nagesh V et al (2006) Survival prediction in highgrade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys 64:876-885 (Pubitemid 43183588)
41. Matsusue E, Fink JR, Rockhill JK et al (2010) Distinction between glioma progression and post-radiation change by combined physiologic MR imaging. Neuroradiology 52:297-306
42. Nowosielski M, Recheis W, Goebel G et al (2011) ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. Neuroradiology 53:291-302
43. Pope WB, Kim HJ, Huo J et al (2009) Recuurent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Neuroradiology 252:182-189
44. Rock JP, Scarpace L, Hearshen D et al (2004) Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery 54:1111-1117
45. Xu M, See SJ, Ng WH et al (2005) Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery 56:919-926
46. Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578 (Pubitemid 29368260)